Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Separately this week, Tekmira announced that a trial date of Oct. 30, 2012 has been set for its litigation with Alnylam Pharmaceuticals and AlCana Technologies.

According to the company, Silicon Valley Bank has agreed to provide a $3 million term loan, which can be drawn down at Tekmira's discretion at any time before Sept. 30, 2012. The loan matures on June 30, 2015, and carries a fixed annual interest rate of 8 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.